Article

Consider the complete picture of a therapy's efficacy

I am writing to add clarification to an article about dry eye that underreports the clinical efficacy and symptom improvement period for cyclosporine (CsA) ophthalmic emulsion 0.05% (Restasis, Allergan) ("Dry eye: what's in the pipeline?" by Joseph Mussoline, MD, Ophthalmology Times, March 15, 2004, Pages 18 to 19).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.